Long
$SCNA The TSLA of BIOPHARM.
Good Evening.
Here we have a Biopharm SSNCA that swung for the fences. Solve ALS. Shorten multi surgery recovery times. Treat depression. After millions spent. They have a ready for phase 3 clinical product with several play , with more in the Pipe. Patented medicine that could break into a 22B adressable market with 20-40% share. This was expensive and took time. They faced several battles with delisting and the stock was crushed by Short Sellers through multiple offerings. The short sellers reaped huge profits in the losses of the pharma bubble and along with many bust companies they have crucified this stock.
With losses mounting it was uncertain if SSNCA would survive through the last rounds to bring their drugs to market. A drug that has shown in current studies to cut ICU and recovery times in a hospital by an entire day. Top line results are expected before EOY and could be ready to report any day. Short sellers have piled on and sucked every drop from this stock as they reap massive gains with years of uncertainty sending long term holders for the hills from the $1000 stock that once was.... The tide has turned.
Recently 12/17202 SSNCA announced a merger with Leading Biosciences. An established privately owned company with positive cashflow and revenues to absorb the remaining costs to bring these new drugs to market. In all stock deal. SSNCA will own 26% of the newly merged company with shareholders of Leading Biosciences to trade as a new formed company Palisades Bio. 22M of outside investment has been pledged to the deal with about
13M Cash in hand that SNCA already holds to continue the phase 3 clinicals and get a drug to market. The merger will give SSNCA shareholders 26% of the proforma value of the new firm which is estimated around 130M.
As a part of the sale: "The merger is structured as a stock-for-stock transaction whereby all of LBS’s outstanding shares of capital stock and securities exercisable for LBS’s common stock will be exchanged for Seneca common stock and securities exercisable for Seneca common stock. On a pro forma basis and based upon the number of shares of Seneca common stock to be issued or issuable in the merger, it is anticipated that Seneca equity holders immediately following the merger will own approximately 26.2% of the combined company and LBS equity holders (inclusive of investors in the financing) immediately following the merger will own approximately 73.8% of the combined company on a fully diluted basis using an adjusted treasury stock method."
The deal means that shareholders will get 26% of a proforma valuation of 134M or 34.84M/17.3M shares, which equates to a $1.99/ share value. The stock is trading at <$1 with short sellers ruthlessly manipulating the ticker into delisting. With the added benefit of a Contingent Value Right (CVR) ; Shareholders of Seneca will also receive one contingent value right (“CVR”) for each share of Seneca common stock (including any warrants exercisable for shares of Seneca common stock) as a dividend. This will entitle the holder to receive, in certain circumstances, a certain percentage the net proceeds, if any, derived from the sale or license of the intellectual property of Seneca. Full details of the CVR agreement will be contained in Seneca’s S-4 to be filed with the SEC. The forthcoming S-4 Should be a bullish catalyst to send this stock soaring as its worth at least 3/share notwithstanding any major good news about progress.
Couple all of this with this years EPS to possibly close 3x better OR MORE than the previous year and light at the end of the tunnel... This could be a mega a catalyst conversion of events. Last 3 EPS 2020FYE not including Q4 ($0.93)loss 2019 FYE ($3.80)loss 2018FYE ($7.54)loss
As expected... FUD is being manufactured from nothing left and right. Short Sellers fought all day for a Penny gain today. Time is up. Watch premarket for an attempted selloff Monday, 12/21/2020 and get ready for Christmas!
On a technical level. Fucking MASSIVE IVHS up to $1.50-2+ Range. Bullish Penent. Support at $0.90. Volume surge.
Low Float. High Short Interest. Pull Back. Catalyst.
SSNCA LONG
Here we have a Biopharm SSNCA that swung for the fences. Solve ALS. Shorten multi surgery recovery times. Treat depression. After millions spent. They have a ready for phase 3 clinical product with several play , with more in the Pipe. Patented medicine that could break into a 22B adressable market with 20-40% share. This was expensive and took time. They faced several battles with delisting and the stock was crushed by Short Sellers through multiple offerings. The short sellers reaped huge profits in the losses of the pharma bubble and along with many bust companies they have crucified this stock.
With losses mounting it was uncertain if SSNCA would survive through the last rounds to bring their drugs to market. A drug that has shown in current studies to cut ICU and recovery times in a hospital by an entire day. Top line results are expected before EOY and could be ready to report any day. Short sellers have piled on and sucked every drop from this stock as they reap massive gains with years of uncertainty sending long term holders for the hills from the $1000 stock that once was.... The tide has turned.
Recently 12/17202 SSNCA announced a merger with Leading Biosciences. An established privately owned company with positive cashflow and revenues to absorb the remaining costs to bring these new drugs to market. In all stock deal. SSNCA will own 26% of the newly merged company with shareholders of Leading Biosciences to trade as a new formed company Palisades Bio. 22M of outside investment has been pledged to the deal with about
13M Cash in hand that SNCA already holds to continue the phase 3 clinicals and get a drug to market. The merger will give SSNCA shareholders 26% of the proforma value of the new firm which is estimated around 130M. As a part of the sale: "The merger is structured as a stock-for-stock transaction whereby all of LBS’s outstanding shares of capital stock and securities exercisable for LBS’s common stock will be exchanged for Seneca common stock and securities exercisable for Seneca common stock. On a pro forma basis and based upon the number of shares of Seneca common stock to be issued or issuable in the merger, it is anticipated that Seneca equity holders immediately following the merger will own approximately 26.2% of the combined company and LBS equity holders (inclusive of investors in the financing) immediately following the merger will own approximately 73.8% of the combined company on a fully diluted basis using an adjusted treasury stock method."
The deal means that shareholders will get 26% of a proforma valuation of 134M or 34.84M/17.3M shares, which equates to a $1.99/ share value. The stock is trading at <$1 with short sellers ruthlessly manipulating the ticker into delisting. With the added benefit of a Contingent Value Right (CVR) ; Shareholders of Seneca will also receive one contingent value right (“CVR”) for each share of Seneca common stock (including any warrants exercisable for shares of Seneca common stock) as a dividend. This will entitle the holder to receive, in certain circumstances, a certain percentage the net proceeds, if any, derived from the sale or license of the intellectual property of Seneca. Full details of the CVR agreement will be contained in Seneca’s S-4 to be filed with the SEC. The forthcoming S-4 Should be a bullish catalyst to send this stock soaring as its worth at least 3/share notwithstanding any major good news about progress.
Couple all of this with this years EPS to possibly close 3x better OR MORE than the previous year and light at the end of the tunnel... This could be a mega a catalyst conversion of events. Last 3 EPS 2020FYE not including Q4 ($0.93)loss 2019 FYE ($3.80)loss 2018FYE ($7.54)loss
As expected... FUD is being manufactured from nothing left and right. Short Sellers fought all day for a Penny gain today. Time is up. Watch premarket for an attempted selloff Monday, 12/21/2020 and get ready for Christmas!
On a technical level. Fucking MASSIVE IVHS up to $1.50-2+ Range. Bullish Penent. Support at $0.90. Volume surge.
Low Float. High Short Interest. Pull Back. Catalyst.
SSNCA LONG
Note
Still long. Have averaged down. Will load heavily at $0.65 if we get there.The 8-K filed today was not easy to understand and gave some numbers that confused some.
Short sellers are moving hard against this stock.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.